New study tracks Durvalumab's Real-World impact on endometrial cancer

NCT ID NCT06890273

Recruiting now Disease control Sponsor: AstraZeneca Source: ClinicalTrials.gov ↗

First seen Jun 25, 2026 · Last updated Jun 27, 2026 · Updated 1 time

Summary

This study is collecting real-world data from 150 women in Germany with advanced or recurrent endometrial cancer. Participants receive standard first-line treatment with chemotherapy plus durvalumab, followed by maintenance therapy with durvalumab alone or with olaparib. The goal is to see how well these treatments work in everyday practice and how they affect patients' quality of life.

What this could mean

Our plain-language read of the trial. This is informational only — not medical advice or a prediction.

Active substance: durvalumab (an immunotherapy drug) combined with chemotherapy (carboplatin and paclitaxel), followed by maintenance with durvalumab alone or with olaparib
What this could lead to: If successful, this could provide real-world evidence that durvalumab-based therapy helps control advanced or recurrent endometrial cancer and improves patient quality of life.
What could go wrong: This is an observational study, not a controlled trial, so results may be less definitive. It is also limited to a German population, which may not apply to all patients.

This is an AI summary of the original study and may miss details. Read our disclaimer.

Get updates

Get notified about this study

Our safety recommendation!

By submitting, you agree to our Terms of use

Conditions

The condition(s) this trial relates to.

endometrial cancer endometrium neoplasm

As listed by the trial registrant

The condition terms exactly as the trial's registrant entered them.

ENDOMETRIAL CANCER

Contacts and locations

Locations

Research Site
RECRUITING

Amberg, Germany
Research Site
RECRUITING

Bad Nauheim, Germany
Research Site
RECRUITING

Bautzen, Germany
Research Site
RECRUITING

Berlin, Germany
Research Site
RECRUITING

Bielefeld, Germany
Research Site
RECRUITING

Bonn, Germany
Research Site
RECRUITING

Borna, Germany
Research Site
RECRUITING

Bottrop, Germany
Research Site
RECRUITING

Brandenburg an der Havel, Germany
Research Site
RECRUITING

Braunschweig, Germany
Research Site
RECRUITING

Cologne, Germany
Research Site
RECRUITING

Dessau, Germany
Research Site
RECRUITING

Dresden, Germany
Research Site
RECRUITING

Ebersberg, Germany
Research Site
RECRUITING

Eggenfelden, Germany
Research Site
RECRUITING

Essen, Germany
Research Site
RECRUITING

Goslar, Germany
Research Site
RECRUITING

Greifswald, Germany
Research Site
RECRUITING

Gütersloh, Germany
Research Site
RECRUITING

Hamburg, Germany
Research Site
RECRUITING

Heilbronn, Germany
Research Site
RECRUITING

Homburg, Germany
Research Site
RECRUITING

Hösbach, Germany
Research Site
RECRUITING

Kiel, Germany
Research Site
RECRUITING

Krefeld, Germany
Research Site
RECRUITING

Kulmbach, Germany
Research Site
RECRUITING

Landshut, Germany
Research Site
RECRUITING

Leipzig, Germany
Research Site
RECRUITING

Limburg, Germany
Research Site
RECRUITING

Lüneburg, Germany
Research Site
RECRUITING

Magdeburg, Germany
Research Site
RECRUITING

Mainz, Germany
Research Site
RECRUITING

München, Germany
Research Site
RECRUITING

Neuruppin, Germany
Research Site
RECRUITING

Neuss, Germany
Research Site
RECRUITING

Nuremberg, Germany
Research Site
RECRUITING

Plauen, Germany
Research Site
RECRUITING

Rotenburg (Wümme), Germany
Research Site
RECRUITING

Siegen, Germany
Research Site
RECRUITING

Solingen, Germany
Research Site
RECRUITING

Stendal, Germany
Research Site
RECRUITING

Torgau, Germany
Research Site
RECRUITING

Traunstein, Germany
Research Site
RECRUITING

Unna, Germany
Research Site
RECRUITING

Wernigerode, Germany
Research Site
RECRUITING

Winnenden, Germany
Research Site
RECRUITING

Witten, Germany
Research Site
RECRUITING

Worms, Germany
Research Site
RECRUITING

Zittau, Germany

More trials for these conditions

Other studies related to the condition(s) this trial covers.